European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency

References

• International Osteoporosis Foundation. Osteoporosis and you. Available at: www.osteofound.org/publications/pdf/osteoporosis_and_you.pdf [last accessed 8 July 2006]
   Google Scholar
• World Health Organization. Osteoporosis: both health organizations and individuals must act now to avoid an impending epidemic. Press release WHO/58 11 October 1999. Available at: www.who.int/inf-pr-1999/en/pr99–58.html [last accessed 4 March 2006]
   Google Scholar
• Chesnut 3rd CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–9
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [Fracture Intervention Trial Research Group]. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344–52
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al.; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344:333–40
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Geusens P, Leufkens HGM, Cooper C. Persistence to bisphosphonate treatment in actual clinical practice. Osteoporosis Int 2005;16\(Suppl 4):P610–Su
   Google Scholar
• Akesson K, Beusterien K, Hebborn A, Leidy NK. Strong patient preference for once-monthly over weekly oral bisphosphonate dosing in postmenopausal osteoporosis. Osteoporosis Int 2005;16\(Suppl 4):P622–Su
   Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis (Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Osteoporosis Int 2000;11:83–91
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077–82
   PubMed Web of Science ®Google Scholar
• Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
   PubMedGoogle Scholar
• Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757–64
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Greenspan SL, Bone 3rd G, et al. Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17: 1988–96
   Google Scholar
• Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporosis Int 2003;14:437–41
   PubMed Web of Science ®Google Scholar
• Silverman SL, Weiss TW, Gold DT, McHorney CA. The PREFER-US study: an evaluation of patient preferences for osteoporosis medications and their attributes. International Society for Clinical Densitometry annual meeting, 1–4 February 2006, San Diego, CA, USA [abstract 210]
   Google Scholar
• Walliser JA, Bolge SC, Sen SS. Patients’ preference for osteoporosis medications: PREFER-International. International Society for Clinical Densitometry annual meeting, 1–4 February 2006, San Diego, CA, USA [abstract 213]
   Google Scholar
• Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005;27:361–76
   PubMed Web of Science ®Google Scholar
• Reginster JY, Felsenberg D, Cooper C, et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporosis Int 2006;17:159–66
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005;353:487–97
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–16
   PubMed Web of Science ®Google Scholar
• Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006;17:922–8
   PubMed Web of Science ®Google Scholar